OX40L (known as TNFSF4, CD252), the cognate ligand of OX40, is a member of the tumor necrosis factor superfamily. The OX40L gene is located on human chromosome 1 and encodes a type II glycoprotein which expressed not only on professional antigen-presenting cells (APCs), but also on CD4+T cells, CD8+T cells, vascular endothelial cells, mast cells and activated NK cells. The interaction between OX40 and OX40L provides a costimulatory signal that strongly regulates the proliferation and survival of T lymphocytes, modulates NKT cell and NK cell function, and contributes to the differentiation and activity of regulatory T cells. Antitumor immunity provides a protective barrier to cancer formation and progression. Accumulating evidence indicates that inflammatory response plays a decisive role at different stages of cancer development and contributes to the initiation and progression of cancer. Moreover, avoiding immune destruction was considered as an emerging hallmark of cancer.
Drug targets for cancer: OX40L research reagents
Other vital drug targets for cancer likeOX40L:
Weiguang Y, Dalin L, Lidan X, et al. Association of OX40L Polymorphisms with Sporadic Breast Cancer in Northeast Chinese Han Population. Lafrenie R, ed. PLoS ONE. 2012;7(8):e41277.